Glutathione and Fatty Liver: Evidence and Advice

Glutathione and fatty liver disease are closely linked, as this powerful antioxidant plays a central role in protecting liver cells from oxidative damage. The liver produces glutathione continuously, but in conditions such as non-alcoholic fatty liver disease (NAFLD) and its newer designation, metabolic dysfunction-associated steatotic liver disease (MASLD), glutathione levels can become significantly depleted. This article explores what glutathione does in the liver, whether supplements can genuinely help, what the current clinical evidence shows, and how supplementation fits alongside the lifestyle changes that remain the cornerstone of fatty liver management.

What is glutathione and why does the liver need it?

Glutathione is the liver's primary endogenous antioxidant, a tripeptide that neutralises reactive oxygen species and supports detoxification. Its depletion in fatty liver disease creates a cycle of worsening oxidative stress and hepatocyte damage.

Glutathione is a major endogenous antioxidant in the liver, a tripeptide molecule composed of three amino acids (glutamate, cysteine and glycine) that the liver synthesises continuously to protect itself from oxidative damage.^[16][17] It plays a central role in neutralising reactive oxygen species, supporting detoxification pathways and maintaining the integrity of liver cells. Without adequate glutathione, hepatocytes become vulnerable to lipid peroxidation, inflammation and cell death.

The liver is heavily exposed to toxic metabolites, including those generated during alcohol metabolism, drug processing and the breakdown of dietary fats, and it maintains high intracellular glutathione concentrations under healthy conditions. This reserve can be depleted by chronic alcohol use, poor nutrition, oxidative stress and conditions such as non-alcoholic fatty liver disease (NAFLD). Clinicians and researchers are increasingly using the term metabolic dysfunction-associated steatotic liver disease (MASLD) to describe what was previously called NAFLD, and metabolic dysfunction-associated steatohepatitis (MASH) in place of NASH. Both sets of terms refer to the same spectrum of conditions, and this article uses them interchangeably.

In fatty liver disease, excess fat accumulation is associated with mitochondrial dysfunction and increased free radical production. This creates a cycle in which oxidative stress depletes glutathione, and reduced glutathione levels allow further oxidative damage to accumulate. Studies in people with NAFLD and NASH have reported lower hepatic glutathione concentrations compared with those with healthy livers, suggesting that glutathione depletion may contribute to disease progression, though the direction of causality is not fully established.^[14][15]

Can taking glutathione supplements actually help a fatty liver?

Glutathione supplements may modestly improve liver enzyme levels in some small trials, but bioavailability is a key limitation and they are not a NICE-recommended treatment for NAFLD or MASLD.

Glutathione supplements may offer some benefit for liver health, but the evidence is still limited and they are not a replacement for established lifestyle interventions. The key challenge with oral glutathione is bioavailability: the molecule can be broken down in the gastrointestinal tract before it reaches the liver intact. Newer formulations, including liposomal glutathione and sublingual preparations, are designed to improve absorption, and some small clinical studies suggest these may raise plasma glutathione levels more effectively than standard oral capsules, though the evidence from human trials remains limited.

A small randomised trial published in BMC Gastroenterology found that oral glutathione supplementation at 300 mg daily for four months was associated with reductions in alanine aminotransferase (ALT) and triglyceride levels in people with NAFLD compared with placebo. While these findings are of interest, the trial was small and further research is needed before any firm conclusions can be drawn.

Intravenous glutathione administration bypasses the absorption problem entirely and has been studied in some research settings, particularly in Japan. However, intravenous glutathione is not licensed for the treatment of NAFLD or MASLD in the UK, and it should not be sought or used outside an authorised clinical trial.^[8] Purchasing injectable glutathione products online carries significant safety risks and is not recommended.

It is also worth noting that the precursor supplement N-acetylcysteine (NAC), which provides cysteine for glutathione synthesis, has been studied in liver conditions and is used clinically in the UK as a prescription medicine for paracetamol overdose management.^[6][7] NAC is not a supplement for self-treatment of fatty liver disease, and it should only be used under medical supervision. Neither glutathione nor NAC is currently recommended by NICE as a treatment for NAFLD or MASLD, and neither should be used as a substitute for medical assessment.^[3][4]

What does the current evidence say about glutathione for liver health?

Current evidence is preliminary, with small human trials suggesting modest improvements in liver enzymes, but no large randomised controlled trial has confirmed clinical benefit such as fibrosis regression.

The current evidence on glutathione and fatty liver is preliminary, with most studies being small, short-term or conducted in animal models. Human clinical trials specifically examining glutathione supplementation in NAFLD, MASLD or MASH remain limited in number and scale, and no regulatory body or clinical guideline, including NICE, the BSG or the BASL, has recommended glutathione as a treatment for liver disease.

Animal studies have demonstrated associations between glutathione depletion and accelerated fatty liver progression, and between restored glutathione levels and reduced markers of hepatic steatosis, inflammation and fibrosis. Translating these findings to humans is not straightforward, because rodent liver metabolism differs from human physiology in important ways.

In human studies, the most cited evidence includes the BMC Gastroenterology trial mentioned above, alongside observational data reporting inverse associations between plasma glutathione levels and the severity of liver fibrosis in patients with chronic liver disease. A pilot study published in Hepatology Research also found that oral liposomal glutathione was associated with improved liver enzyme profiles and reduced oxidative stress markers in a small cohort of NAFLD patients. These findings are preliminary and have not been replicated in large trials.

It is also worth clarifying that the MHRA is responsible for licensing medicines in the UK rather than issuing clinical treatment recommendations; guidance on managing fatty liver disease comes from NICE, the BSG and the BASL.

Overall, the evidence suggests that:

• Glutathione depletion is associated with worse liver outcomes in people with fatty liver disease.

• Supplementation may modestly improve liver enzyme levels in some studies, but effect sizes in human trials are small.

• Bioavailability remains a significant limitation for standard oral formulations.

• No large randomised controlled trial has yet confirmed clinical benefit in terms of hard outcomes such as fibrosis regression or reduced progression to cirrhosis.

Researchers continue to investigate glutathione-based therapies, and the field is evolving. Patients should discuss any supplementation with their GP or hepatologist before starting.

Safety considerations and who should speak to their GP first

Glutathione supplements are generally well tolerated but should not be taken without GP advice if you have a liver condition, are pregnant, are on prescribed medicines, or have a history of asthma.

Glutathione supplements are generally considered well tolerated at doses used in clinical studies, but that does not mean they are appropriate for everyone. Certain groups should speak to their GP before taking glutathione or related supplements such as NAC.

Speak to your GP before starting glutathione supplements if you:

• Have been diagnosed with any liver condition, including NAFLD, MASLD, NASH, MASH, cirrhosis or hepatitis.

• Are taking prescribed medicines. Glutathione may theoretically interact with some drugs, including immunosuppressants and certain chemotherapy agents. This caution is precautionary; if you are receiving cancer treatment, speak to your oncology team before taking any supplement.

• Are pregnant or breastfeeding. There is insufficient safety data to recommend glutathione supplementation during pregnancy or lactation, and it should be avoided unless specifically advised by a clinician.

• Have a history of asthma, as inhaled glutathione has been associated with bronchospasm in some individuals.^[2]

High-dose supplementation has not been associated with serious adverse effects in short-term trials, but long-term safety data in humans are limited. Some people report mild gastrointestinal symptoms, including bloating or loose stools, particularly with higher doses.

If you experience any of the following while taking glutathione supplements, stop taking them and contact your GP or call NHS 111: persistent abdominal pain, jaundice (yellowing of the skin or eyes), dark urine, or unexplained fatigue. These symptoms may indicate liver problems that require medical assessment. If symptoms are severe or rapidly worsening, call 999 or go to your nearest emergency department.

Suspected adverse reactions to supplements can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Reports from patients and carers are welcome and help the MHRA monitor the safety of products available in the UK.

What other lifestyle changes support liver recovery alongside glutathione?

Weight loss, a Mediterranean diet and regular physical activity are the most evidence-based interventions for fatty liver, as outlined in NICE NG49, and should take priority over supplementation.

Lifestyle modification remains the most evidence-based approach to managing fatty liver disease. NICE guidance on NAFLD (NG49) emphasises weight management, dietary change and physical activity as the cornerstones of treatment.^[3][4] Glutathione supplementation, if considered at all, should be viewed as an adjunct to these measures rather than a standalone intervention.

Key lifestyle strategies supported by evidence include:

• Weight loss: Even a modest reduction of 5 to 10 per cent of body weight has been shown to reduce hepatic steatosis and improve liver enzyme levels. A loss of 10 per cent or more is associated with histological improvement in NASH or MASH, as reflected in BSG and BASL guidance.

• Dietary change: A Mediterranean-style diet, rich in vegetables, legumes, whole grains, olive oil and oily fish, is associated with reduced liver fat and improved metabolic markers. Reducing ultra-processed foods, added sugars and saturated fats is particularly important.

• Physical activity: Both aerobic exercise and resistance training reduce liver fat independently of weight loss.^[19][20] UK Chief Medical Officers' guidelines recommend at least 150 minutes of moderate-intensity activity per week for adults.^[9][10]

• Alcohol reduction: Even in non-alcoholic or metabolic fatty liver disease, alcohol can accelerate liver damage. Staying within the UK Chief Medical Officers' low-risk guidelines (no more than 14 units per week, spread across three or more days) is advisable.^[12][13]

• Avoiding hepatotoxic substances: Some over-the-counter medicines, herbal remedies and high-dose supplements can stress the liver. Always inform your GP of everything you are taking.

If you have been diagnosed with fatty liver disease, your GP may arrange blood tests to assess the degree of liver scarring (fibrosis). Tools such as the FIB-4 score and the non-alcoholic fatty liver disease fibrosis score (NFS) are used in primary care to identify people who may need referral to a hepatologist for further assessment, including the Enhanced Liver Fibrosis (ELF) test, in line with NICE NG49. Early identification of significant fibrosis allows timely specialist input and closer monitoring.

For people seeking structured support with weight management, Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where clinically appropriate options may be discussed. Addressing the metabolic drivers of fatty liver, including insulin resistance and obesity, is likely to have a far greater impact on liver health than supplementation alone.

Scientific References

1. Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: a pilot study. BMC Gastroenterology..
2. Nebulized glutathione induces bronchoconstriction in patients with mild asthma. PubMed..
3. Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management (NG49)..
4. Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management (NG49) — full guideline PDF..
5. Non-alcoholic fatty liver disease (NAFLD). NHS..
6. Acetylcysteine. BNF — NICE..
7. Intravenous N-acetylcysteine (NAC) for paracetamol overdose: reminder of authorised dose regimen. MHRA Drug Safety Update..
8. Semaglutide (Wegovy) approved to treat form of liver disease. GOV.UK..
9. Physical activity guidelines: UK Chief Medical Officers' report. GOV.UK..
10. UK Chief Medical Officers' physical activity guidelines (full report). GOV.UK..
11. Physical activity guidelines for adults aged 19 to 64. NHS..
12. Alcohol consumption: advice on low risk drinking. UK Chief Medical Officers. GOV.UK..
13. Chapter 12: alcohol — Delivering Better Oral Health: an evidence-based toolkit for prevention. GOV.UK..
14. Blood oxidative stress markers in non-alcoholic steatohepatitis and how it correlates with diet. Scandinavian Journal of Gastroenterology..
15. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental..
16. The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress. Current Neuropharmacology..
17. Roles of MRP2 and oatp1 in hepatocellular export of reduced glutathione. Seminars in Liver Disease..
18. Systematic review of ophthalmate as a novel biomarker of hepatic glutathione depletion. Clinical Nutrition..
19. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of body weight changes. PubMed..
20. Structured Exercise Interventions and Hepatic-Metabolic Outcomes in Adults with MASLD: A Narrative Review of Randomized Controlled Trials. International Journal of Molecular Sciences..
21. Moderate-Intensity Aerobic vs Resistance Exercise and Dietary Modification in Patients With Nonalcoholic Fatty Liver Disease: A Randomized Clinical Trial. Clinical and Translational Gastroenterology..
22. Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology..

Frequently Asked Questions